Search

Your search keyword '"Lamm, Donald L"' showing total 585 results
Start Over Author "Lamm, Donald L"
585 results on '"Lamm, Donald L"'

1. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author

Li, Roger, Shah, Paras H., Stewart, Tyler F., Nam, Jong Kil, Bivalacqua, Trinity J., Lamm, Donald L., Uchio, Edward M., Geynisman, Daniel M., Jacob, Joseph M., Meeks, Joshua J., Dickstein, Rian, Pearce, Shane M., Kang, Seok Ho, Jung, Seung Il, Kamat, Ashish M., Burke, James M., Keegan, Kirk A., and Steinberg, Gary D.

Published
2024
Full Text
View/download PDF

2. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection

Author

Li, Roger, Hensley, Patrick J., Gupta, Shilpa, Al-Ahmadie, Hikmat, Babjuk, Marko, Black, Peter C., Brausi, Maurizio, Bree, Kelly K., Fernández, Mario I., Guo, Charles C., Horowitz, Amir, Lamm, Donald L., Lerner, Seth P., Lotan, Yair, Mariappan, Paramananthan, McConkey, David, Mertens, Laura S., Mir, Carmen, Ross, Jeffrey S., O’Donnell, Michael, Palou, Joan, Pohar, Kamal, Steinberg, Gary, Soloway, Mark, Spiess, Philippe E., Svatek, Robert S., Tan, Wei Shen, Taoka, Rikiya, Buckley, Roger, and Kamat, Ashish M.

Published
2024
Full Text
View/download PDF

3. Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author

Li, Roger, Shah, Paras H., Stewart, Tyler F., Nam, Jong Kil, Bivalacqua, Trinity J., Lamm, Donald L., Uchio, Edward M., Geynisman, Daniel M., Jacob, Joseph M., Meeks, Joshua J., Dickstein, Rian, Pearce, Shane M., Kang, Seok Ho, Jung, Seung Il, Kamat, Ashish M., Burke, James M., Keegan, Kirk A., and Steinberg, Gary D.

Published
2024
Full Text
View/download PDF

4. Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial

Author

Li, Roger, Shah, Paras H., Stewart, Tyler F., Nam, Jong Kil, Bivalacqua, Trinity J., Lamm, Donald L., Uchio, Edward M., Geynisman, Daniel M., Jacob, Joseph M., Meeks, Joshua J., Dickstein, Rian, Pearce, Shane M., Kang, Seok Ho, Jung, Seung Il, Kamat, Ashish M., Burke, James M., Keegan, Kirk A., and Steinberg, Gary D.

Published
2024
Full Text
View/download PDF

5. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

Author

Hahn, Noah M., O'Donnell, Michael A., Efstathiou, Jason A., Zahurak, Marianna, Rosner, Gary L., Smith, Jeff, Kates, Max R., Bivalacqua, Trinity J., Tran, Phuoc T., Song, Daniel Y., Baras, Alex S., Matoso, Andres, Choi, Woonyoung, Smith, Kellie N., Pardoll, Drew M., Marchionni, Luigi, McGuire, Bridget, Grace Phelan, Mary, Johnson, Burles A., III, O'Neal, Tanya, McConkey, David J., Rose, Tracy L., Bjurlin, Marc, Lim, Emerson A., Drake, Charles G., McKiernan, James M., Deutsch, Israel, Anderson, Christopher B., Lamm, Donald L., Geynisman, Daniel M., Plimack, Elizabeth R., Hallman, Mark A., Horwitz, Eric M., Al-Saleem, Essel, Chen, David Y.T., Greenberg, Richard E., Kutikov, Alexander, Guo, Gordon, Masterson, Timothy A., Adra, Nabil, and Kaimakliotis, Hristos Z.

Published
2023
Full Text
View/download PDF

6. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

Author

Packiam, Vignesh T., Lamm, Donald L., Barocas, Daniel A., Trainer, Andrew, Fand, Benjamin, Davis, Ronald L., III, Clark, William, Kroeger, Michael, Dumbadze, Igor, Chamie, Karim, Kader, A. Karim, Curran, Dominic, Gutheil, John, Kuan, Arthur, Yeung, Alex W., and Steinberg, Gary D.

Published
2018
Full Text
View/download PDF

7. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG

Author

Steinberg, Ryan L., Packiam, Vignesh T., Thomas, Lewis J., Brooks, Nathan, Vitale, Andrew, Mott, Sarah L, Crump, Trafford, Wang, Jonathan, DeWolf, William C., Lamm, Donald L, Kates, Max, Hyndman, M. Eric, Kamat, Ashish M., Bivalacqua, Trinity J., Nepple, Kenneth G., and O'Donnell, Michael A.

Published
2022
Full Text
View/download PDF

12. A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis).

Author

Kulkarni, Girish S., primary, Richards, Kyle A, additional, Black, Peter C., additional, Rendon, Ricardo A., additional, Chin, Joseph, additional, Shore, Neal D., additional, Jayram, Gautam, additional, Kramolowsky, Eugene V., additional, Saltzstein, Daniel, additional, Agarwal, Piyush K., additional, Belkoff, Laurence, additional, O'Donnell, Michael A., additional, Kamat, Ashish M., additional, Jewett, Michael A.S., additional, Lamm, Donald L., additional, DeGruttola, Victor, additional, Mandel, Arkady, additional, Dumoulin-White, Roger, additional, and Kassouf, Wassim, additional

Published
2023
Full Text
View/download PDF

15. Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder Cancer

Author

Thomas, Lewis J., primary, Steinberg, Ryan L., additional, Packiam, Vignesh T., additional, McElree, Ian M., additional, Brooks, Nathan, additional, Vitale, Andrew, additional, Hyndman, Eric, additional, Crump, Trafford, additional, Rao, Mounica Y., additional, Lamm, Donald L., additional, Daniels, Marcus J., additional, Kates, Max, additional, Nagaraju, Supriya, additional, Kamat, Ashish M., additional, Bivalacqua, Trinity J., additional, Mott, Sarah L., additional, Nepple, Kenneth G., additional, and O'Donnell, Michael A., additional

Published
2022
Full Text
View/download PDF

17. Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter

Author

Kamat, Ashish M., primary, Lobo, Niyati, additional, Lerner, Seth P., additional, Li, Roger, additional, Matulay, Justin T., additional, Palou, Joan, additional, Witjes, J. Alfred, additional, Rouprêt, Morgan, additional, Smith, Angela B., additional, Chang, Sam S., additional, Shore, Neal D., additional, Steinberg, Gary D., additional, Dinney, Colin P., additional, Svatek, Robert S., additional, and Lamm, Donald L., additional

Published
2022
Full Text
View/download PDF

18. CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Author

Li, Roger, primary, Steinberg, Gary D., additional, Uchio, Edward M., additional, Lamm, Donald L., additional, Shah, Paras, additional, Kamat, Ashish M., additional, Bivalacqua, Trinity, additional, Packiam, Vignesh T., additional, Chisamore, Michael Jon, additional, McAdory, John, additional, Grandi, Paola, additional, Hnat, Nataliya, additional, and Burke, James, additional

Published
2022
Full Text
View/download PDF

32. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer

Author

Steinberg, Ryan L., primary, Thomas, Lewis J., additional, Brooks, Nathan, additional, Mott, Sarah L., additional, Vitale, Andrew, additional, Crump, Trafford, additional, Rao, Mounica Y., additional, Daniels, Marcus J., additional, Wang, Jonathan, additional, Nagaraju, Supriya, additional, DeWolf, William C., additional, Lamm, Donald L., additional, Kates, Max, additional, Hyndman, M. Eric, additional, Kamat, Ashish M., additional, Bivalacqua, Trinity J., additional, Nepple, Kenneth G., additional, and O’Donnell, Michael A., additional

Published
2020
Full Text
View/download PDF

46. Superficial bladder cancer: Practical management strategies. (Symposium)

Author

Schellhammer, Paul F., Bostwick, David G., Grossman, H. Barton, Herr, Harry W., Lamm, Donald L., and O'Donnell, Michael A.

Subjects
Bladder cancer -- Care and treatment, Cystoscopy, Hematuria -- Diagnosis, Tumor markers -- Physiological aspects, Diet in disease -- Research, Health
Published
2002

48. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder

Author

Lamm, Donald L., Blumenstein, Brent A., Crawford, E. David, Montie, James E., Scardino, Peter, Grossman, H. Barton, Stanisic, Thomas H., Smith, Joseph A., Jr., Sullivan, Jerry, Sarosdy, Michael F., Crissman, John D., and Coltman, Charles A.

Subjects
Bladder cancer -- Drug therapy, Doxorubicin -- Evaluation, BCG -- Evaluation, Bladder cancer -- Development and progression
Abstract

Immunotherapy using bacille Calmette-Guerin (BCG) is an approved treatment for carcinoma in situ (early stage cancer) of the bladder, and its superiority over surgery alone and as a preventive agent has been shown in several randomized, controlled trials. However, randomized studies have not been carried out to compare the effectiveness of BCG with that of chemotherapeutic drugs such as doxorubicin (known to prevent tumor recurrence). A study was conducted of 262 patients with either rapidly recurrent (131 patients) or in situ transitional-cell carcinoma of the bladder. Patients were treated prophylactically if they were tumor-free, and therapeutically if they had carcinoma in situ. They were randomly assigned to receive either BCG or doxorubicin in the bladder, with the option of changing to the other treatment if recurrence took place. Patients were followed-up for a median time of 65 months, with treatment effectiveness evaluated by biopsy and urinalysis. Treatment with BCG was associated with a greater number of adverse effects, few of which were severe; the number of at least moderate effects was similar in the two groups. BCG treatment led to a greater proportion (70 percent) of complete responses (complete disappearance of disease) than doxorubicin (34 percent) in patients with carcinoma in situ, and a complete response was seen sooner after treatment started with BCG. Recurrences, when seen, took place after 5.1 months (median value) in doxorubicin patients and after 39 months in BCG patients. Those who received BCG had a probability, after five years, of disease-free survival of 45 percent, compared with 18 percent after doxorubicin. Patients with tumors without carcinoma in situ had a probability of disease-survival at five years of 37 percent with BCG and of 17 percent with doxorubicin, and a time to treatment failure of 10.4 months and 22.5 months, respectively. These findings, which include results from 46 medical institutions, indicate that BCG is no more toxic than standard chemotherapy and that it can be administered safely and effectively. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results